Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
FibroBiologics, Inc. issued to purchase up to 313,433 shares of Common Stock of warrant to Placement Agent (H.C. Wainwright & Co., LLC) for issued as compensation; exercise price $0.4188 per share.
- Security
- warrant
- Shares
- to purchase up to 313,433 shares of Common Stock
- Purchaser
- Placement Agent (H.C. Wainwright & Co., LLC)
- Consideration
- issued as compensation; exercise price $0.4188 per share
Exact text from the filing
Additionally, the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 313,433 shares of Common Stock), at an exercise price of $0.4188 per share (the “Placement Agent Warrants”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
FibroBiologics, Inc. issued to purchase 4,477,614 shares of Common Stock of warrant to institutional investors (the Purchasers) for exercise price $0.335 per share; no additional consideration at issuance.
- Security
- warrant
- Shares
- to purchase 4,477,614 shares of Common Stock
- Purchaser
- institutional investors (the Purchasers)
- Consideration
- exercise price $0.335 per share; no additional consideration at issuance
Exact text from the filing
4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.335 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchasers, in a concurrent private placement, warrants to
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2025-11-24).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- approximately $1.5 million
- Effective
- 2025-11-24
Exact text from the filing
On November 24, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).
View on SEC.gov